Patent Invalidation in Galway.

A patent invalidation Galway strategy starts with a fact that surprises litigants used to the Unified Patent Court: Ireland is not in it. Ireland signed the Agreement on a Unified Patent Court but has never ratified it, because ratification would transfer patent jurisdiction to an international court and so requires amending Article 29 of the Constitution — a national referendum. One was scheduled for June 2024, then deferred with no new date set. So a European patent validated in Ireland, or an Irish national patent, is attacked here nationally. That matters more in Galway than almost anywhere else, because Galway is one of the densest medical-device clusters on Earth, and device patents on stents, catheters and delivery systems are exactly what gets fought over.

Why patent invalidation Galway cases are decided nationally, not by the UPC

Across most of Europe a European patent can now be revoked centrally at the Unified Patent Court, with a single ruling reaching seventeen or more member states. Ireland deliberately sits outside that system. It signed the UPC Agreement over a decade ago but has never ratified, and ratification is not a matter the Government can settle by legislation alone. Transferring the power to decide patent validity to an international court engages Article 29 of the Irish Constitution, which means the change must be put to the people in a referendum.

That referendum has proved hard to hold. A vote was announced for June 2024 to run alongside the European and local elections, then deferred in April 2024 so there could be more public debate. No replacement date has been confirmed. The Government still says it wants to join, but until the electorate votes yes, Ireland stays out. For a patent invalidation Galway defendant this is the single most important structural fact: whatever happens at the UPC in Munich or Paris, an Irish patent right lives or dies in the Irish system.

The practical upshot is jurisdictional independence. A competitor cannot drag your Irish rights into a central European revocation action, and you cannot knock out the Irish designation of a European patent through the UPC. You attack it at home, under the Patents Act 1992 (as amended), before an Irish forum applying Irish procedure. For device makers whose manufacturing and R&D sit in Galway, that keeps the fight close to the evidence, the witnesses and the engineering that actually decides it.

Two Irish routes: the High Court IP and Technology List or the Controller at the IPOI

Ireland gives a challenger two doors. The first is the High Court. Since 22 October 2021 patent validity and revocation actions have been channelled into a dedicated Intellectual Property and Technology List, a sub-division of the Commercial Court created under a revised Order 63A of the Rules of the Superior Courts. A judge can assign to it any intellectual-property proceedings, or matters of genuine technological complexity, which is precisely what a stent or catheter validity dispute is. Cases are actively case-managed toward trial rather than left to drift.

Invalidity is usually raised as a counterclaim once a patent owner sues for infringement, or brought as a standalone revocation action by a company that wants clear air to launch a product. Proceedings start with a plenary summons, and entry to the Commercial Court list is by motion with a solicitor’s certificate explaining why the case belongs there. Disputes worth under one million euro can still be admitted, though very small matters below the Circuit Court threshold fall away, so most serious device fights qualify comfortably.

The second door is administrative. Under section 57 of the Patents Act 1992, any person may apply for revocation not only to the Court but to the Controller of the Intellectual Property Office of Ireland (IPOI), the national office based in Kilkenny. The Controller route can be lower-cost and useful where the attack rests squarely on documentary prior art rather than a heavy factual dispute needing live cross-examination. Choosing between the High Court and the Controller — forum, cost, speed and the kind of evidence each handles well — is an early strategic call in every matter.

Galway, Europe’s medical-device capital, and the patents fought here

Galway is not a general industrial city; it is a medical-technology capital. More than one hundred medtech companies cluster in and around the city, and eight of the world’s top ten medical-device firms have operations here, including Medtronic, Boston Scientific and Abbott. Medtronic opened its first European manufacturing plant in Galway in 1999, Boston Scientific followed with major sites, and the anchor multinationals pulled in a dense web of suppliers, contract manufacturers and start-ups. The University of Galway and the BioInnovate programme feed a steady stream of new device ventures into the same ecosystem.

This is overwhelmingly cardiovascular and interventional technology. Boston Scientific’s Galway operation alone makes heart and oesophageal stents, vascular balloons and drug-coated devices, and its recent expansion targets structural heart, cardiovascular and endoscopy programmes. The patents that get litigated here therefore read on stents, guidewires, balloon and PTA catheters, delivery and deployment systems, drug-coated balloons, ablation catheters and structural-heart implants. These are crowded, incremental fields where dozens of players patent narrow improvements over the same base technology.

That density is what makes invalidity such a live tool in Galway. When a claim covers a small design tweak to a stent strut or a catheter tip, the odds are high that someone, somewhere, disclosed the same idea earlier. The task is to find that disclosure and prove it was public before the priority date. A patent invalidation Galway search that understands device engineering — and knows where medical-device prior art actually surfaces — is worth far more than a keyword sweep of patent databases.

Where the decisive prior art hides in medical-device cases

Medical-device validity fights turn on a different evidence base than software or pure chemistry. The killer reference for a stent, catheter or delivery-system claim is rarely the first patent a keyword search returns. It tends to sit in the clinical and regulatory record, in older device families, and in the specialist conference literature that a patent examiner almost never retrieves during prosecution. Knowing those channels, and being able to date what you find, is the core of the job.

• US FDA regulatory disclosures — 510(k) clearance summaries and PMA documents that describe a marketed device, often years before a later patent claims the same feature
• Clinical trial and journal literature — peer-reviewed cardiovascular and interventional studies that publish device designs and performance data with firm publication dates
• Interventional conference abstracts — presentations and proceedings from meetings such as TCT and EuroPCR where new device concepts are unveiled first
• Older and expired device patent families — earlier stent, balloon and delivery-system patents argued as novelty anticipations or inventive-step combinations
• Standards, guidance and product manuals — ISO device standards, instructions-for-use and datasheets that fix technical detail to a provable date

The second half of the work is proof of public availability. A reference only defeats a claim if it was genuinely available to the public before the priority date the patent relies on. We treat dating as evidence in its own right — capturing journal issue dates, conference programmes, regulatory clearance dates, archive timestamps and library holdings — so the disclosure survives cross-examination in the High Court rather than collapsing into a side argument about authenticity.

Revocation grounds under the Patents Act 1992

Irish revocation is governed by section 58 of the Patents Act 1992, which sets out a defined list of grounds. The workhorse is patentability: a patent can be revoked because its subject matter is not patentable, which in practice means it lacks novelty or inventive step over the prior art. For the incremental device improvements common in Galway, inventive step is the battleground — whether a small change to a known stent or catheter would have been obvious to a skilled engineer at the priority date.

The statute reaches beyond novelty, though. A patent is also vulnerable where the specification does not disclose the invention clearly and completely enough for a skilled person to carry it out (insufficiency), where the granted matter extends beyond what was in the application as filed (added matter), where protection was widened by an impermissible amendment, or where the proprietor is not the person entitled to the patent. A single well-built invalidity case often pleads several of these grounds in the alternative.

Because Ireland validates the Irish designation of European patents under substantially the same substantive standards the EPO applies, prior art assembled for an EPO opposition frequently does double duty in an Irish revocation, and vice versa. Where an EPO opposition is still open, coordinating it with an Irish national attack — so the same references and the same claim analysis carry across both — is a natural efficiency. The search is the shared asset that anchors either forum.

How PerspireIP builds a patent invalidation Galway case

Every engagement follows the same disciplined path. We chart the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date printed on the cover. For device subject matter we run patent retrieval and deep non-patent-literature searching in parallel, then push hard into the regulatory, clinical and conference record where medical-device disclosures really live.

• Claim charting mapped to the section 58 grounds — novelty, inventive step, insufficiency and added matter
• Parallel patent and non-patent searching tuned to stents, catheters, balloons, delivery systems and structural-heart implants
• Targeted retrieval of FDA 510(k) and PMA records, clinical journals and interventional conference abstracts
• Public-availability dating evidenced for every reference, ready for the High Court record or a Controller proceeding
• Art sized to your forum and coordinated with any parallel EPO opposition on the same European patent

We work alongside your Irish patent solicitors and counsel as a specialist search partner, deliver to Commercial Court and IPOI deadlines, and keep every engagement confidential. Whether you are a Galway device manufacturer facing an infringement claim in the High Court IP and Technology List, a start-up clearing a product before launch, or litigation counsel weighing a Controller revocation, we scale to fit. Because the whole case runs on the strength of the art, send us the patent number and your key dates, and we will scope a patent invalidation Galway project within one business day.

IP Landscape & Resources in Galway

Key intellectual-property authorities and venues relevant to Galway:

• Intellectual Property Office of Ireland (IPOI) — the Irish national patent office in Kilkenny, whose Controller can hear applications to revoke a patent under section 57 of the Patents Act 1992
• Courts Service of Ireland — administers the High Court and its Commercial Court Intellectual Property and Technology List, where Irish patent validity and revocation actions are heard
• Patents Act 1992 (Irish Statute Book) — the governing statute, whose sections 57 and 58 set out who may seek revocation and the grounds on which an Irish patent can be revoked
• World Intellectual Property Organization (WIPO) — administers the international patent framework and WIPO Lex, where Ireland's patent legislation and treaty commitments are published

Request a Patent Invalidation Search in Galway

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions